RayKnowChina Research Map
Shortlist

Not yet recruitingLymphomaPhase 2

Registered title, quoted from ClinicalTrials.gov

ARTA-based Chemo-free Bridging/Maintenance Therapy in CAR-T Treatment for High-Risk R/R B-NHL Ineligible for HDCT and ASCT

An open trial on lymphoma, registered on ClinicalTrials.gov. Led by Ruijin Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorRuijin Hospital上海交通大学医学院附属瑞金医院ShanghaiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06646666, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 8

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (8 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Histologically confirmed as B-cell non-Hodgkin lymphoma, including:

    Inclusion criterion 3

  3. Refractory: At least partial response (PR) after the last chemotherapy or relapse within 12 months after autologous transplantation.

    Inclusion criterion 11

    Relapsed: Complete response (CR) after the last chemotherapy, followed by relapse before enrollment, or relapse or progression 12 months or longer after autologous transplantation.

    Inclusion criterion 12

    Received lenalidomide, calcineurin inhibitors, chemotherapy (e.g., methotrexate, cyclophosphamide, ifosfamide, nitrogen mustard, or melphalan), mycophenolate, thalidomide, immunosuppressive antibodies (e.g., anti-TNF, anti-IL6, or anti-IL6R), radiation therapy, or any drug that binds FKBP12 (e.g., rapamycin, tacrolimus, everolimus) within 4 weeks prior to PBMC collection.

    Exclusion criterion 17

  4. ECOG score = 2

    Inclusion criterion 16

  5. Creatinine clearance < 60 mL/min

    Inclusion criterion 19

    ALT or AST > 2× upper limit of normal (ULN)

    Inclusion criterion 20

    Hemoglobin ≥ 80 g/L

    Inclusion criterion 26

    Platelets ≥ 50 × 10\^9/L

    Inclusion criterion 27

    ALT/AST ≤ 5 × ULN and total bilirubin < 2 × ULN

    Inclusion criterion 28

    Creatinine clearance ≥ 30 mL/min

    Inclusion criterion 29

  6. Measurable target lesions: lymph nodes ≥ 15 mm in longest diameter, or extranodal lesions > 10 mm.

    Inclusion criterion 22

  7. Chronic HBV carriers with HBV DNA ≥ 500 IU/mL.

    Exclusion criterion 5

    Positive HCV RNA in patients with positive HCV antibodies.

    Exclusion criterion 6

    Positive HIV antibodies (HIV-Ab).

    Exclusion criterion 7

    History of malignancies other than the indication for this trial within the last 5 years, except for in situ cancers (e.g., cervical, bladder, breast) or non-melanoma skin cancer.

    Exclusion criterion 15

  8. Pregnant or breastfeeding women, or men or women of childbearing potential unwilling to use contraception during the trial and for 2 years after RJ CAR-T 002 cell infusion.

    Exclusion criterion 18

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06646666, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Willingly sign the informed consent form.
  • Age ≥ 18 years, any gender.
  • Histologically confirmed as B-cell non-Hodgkin lymphoma, including:
  • Diffuse large B-cell lymphoma (DLBCL) not otherwise specified (DLBCL-NOS)
  • Transformed follicular lymphoma (tFL)
  • High-grade B-cell lymphoma (HGBL) with MYC, BCL2, and/or BCL6 rearrangements
  • High-grade B-cell lymphoma not otherwise specified (HGBL-NOS)
  • Primary mediastinal large B-cell lymphoma (PMBL)
  • Follicular lymphoma grade 3b (FL3b)
  • Patients must have experienced at least one line of treatment for relapsed or refractory disease, meeting the following definitions:
  • Refractory: At least partial response (PR) after the last chemotherapy or relapse within 12 months after autologous transplantation.
  • Relapsed: Complete response (CR) after the last chemotherapy, followed by relapse before enrollment, or relapse or progression 12 months or longer after autologous transplantation.
  • Maximum tumor diameter (long axis) > 4 cm.
  • Evaluator determines that the patient does not meet HDCT/ASCT criteria and meets at least one of the following:
  • Age ≥ 60 years
  • ECOG score = 2
  • FEV1% or DLCO% ≤ 60%
  • LVEF < 50%
  • Creatinine clearance < 60 mL/min
  • ALT or AST > 2× upper limit of normal (ULN)
  • Patient unwilling to receive high-dose chemotherapy and autologous stem cell transplantation.
  • Measurable target lesions: lymph nodes ≥ 15 mm in longest diameter, or extranodal lesions > 10 mm.
  • Expected survival ≥ 12 weeks.
  • Laboratory tests must meet the following requirements at screening:
  • Lymphocyte count ≥ 0.1 × 10\^9/L
  • Hemoglobin ≥ 80 g/L
  • Platelets ≥ 50 × 10\^9/L
  • ALT/AST ≤ 5 × ULN and total bilirubin < 2 × ULN
  • Creatinine clearance ≥ 30 mL/min
  • Lung function: ≤ CTCAE grade 1 dyspnea, and oxygen saturation (SpO2) ≥ 92% in room air.
  • LVEF ≥ 40%
  • Patients with primary central nervous system lymphoma are allowed (secondary CNS lymphoma is not allowed).
  • Sufficient venous access for apheresis, and no other contraindications for blood cell separation; female participants of childbearing potential must have a negative pregnancy test at screening.

Exclusion Criteria:

  • History of allergy to any component of the cellular product or study treatment.
  • History of allogeneic hematopoietic stem cell transplantation.
  • History of organ transplantation.
  • Patients with active viral hepatitis requiring treatment, including:
  • Chronic HBV carriers with HBV DNA ≥ 500 IU/mL.
  • Positive HCV RNA in patients with positive HCV antibodies.
  • Positive HIV antibodies (HIV-Ab).
  • Positive Treponema pallidum antibodies (TP-Ab).
  • Elevated CMV DNA or EBV DNA above normal limits.
  • Clinical significance of CNS diseases
  • Presence of active primary central nervous system lymphoma.
  • Prior treatment with other genetically modified T-cell therapies or CAR-T therapies.
  • Severe genetic diseases or autoimmune diseases (e.g., systemic lupus erythematosus).
  • Thromboembolic events (e.g., myocardial infarction, pulmonary embolism, deep vein thrombosis) within 6 months prior to screening.
  • History of malignancies other than the indication for this trial within the last 5 years, except for in situ cancers (e.g., cervical, bladder, breast) or non-melanoma skin cancer.
  • Active infections requiring systemic treatment or uncontrolled infections.
  • Received lenalidomide, calcineurin inhibitors, chemotherapy (e.g., methotrexate, cyclophosphamide, ifosfamide, nitrogen mustard, or melphalan), mycophenolate, thalidomide, immunosuppressive antibodies (e.g., anti-TNF, anti-IL6, or anti-IL6R), radiation therapy, or any drug that binds FKBP12 (e.g., rapamycin, tacrolimus, everolimus) within 4 weeks prior to PBMC collection.
  • Pregnant or breastfeeding women, or men or women of childbearing potential unwilling to use contraception during the trial and for 2 years after RJ CAR-T 002 cell infusion.
  • Participation in other drug clinical trials (e.g., new drug trials, registrational studies, investigator-initiated trials) within 4 weeks prior to PBMC collection.
  • Researcher's judgment that the patient is unsuitable for the trial (e.g., poor compliance, drug abuse).
  • Vaccination with live or attenuated vaccines within 3 months prior to PBMC collection, or expected vaccination during the trial.

Quoted from ClinicalTrials.gov, NCT06646666, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06646666, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06646666